BOA Biomedical

BOA Biomedical is a medical technology company focused on rapidly diagnosing and treating severe infectious diseases, including sepsis, antibiotic-resistant infections, and pandemic pathogens. Founded in 2018 as a Miraki Innovation company, it develops platform technologies licensed from Harvard University’s Wyss Institute, including an extracorporeal blood cleansing therapeutic known as GARNET. This system is designed to physically remove a broad spectrum of pathogens—such as bacteria, fungi, viruses, and parasites—and their inflammation-triggering debris directly from a patient’s bloodstream to stabilize health. The company also develops companion diagnostic tools, such as the AGATE, Amethyst, and Rubellite systems, which aim to provide rapid, culture-free identification of pathogens to improve clinical decision-making.

By addressing the root causes of infection rather than just symptoms, BOA Biomedical aims to provide essential countermeasures for hospital-acquired infections, biothreats, and global outbreaks. Its technology seeks to solve the critical issue of slow conventional diagnostic methods, which often take days to identify pathogens. The company has moved its GARNET therapeutic into first-in-human clinical trials to evaluate safety and clinical utility, positioning its platform as a potential solution for patients suffering from life-threatening bloodstream infections. The firm has collaborated with government research agencies, including the U.S. Department of Defense, to advance these medical technologies.